Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $12.92 in the prior trading day, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $12.88, down -0.31%. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 1.29 million shares were traded. DNA stock price reached its highest trading level at $13.67 during the session, while it also had its lowest trading level at $12.775.
Ratios:
Our goal is to gain a better understanding of DNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.88 and its Current Ratio is at 4.88. In the meantime, Its Debt-to-Equity ratio is 0.67 whereas as Long-Term Debt/Eq ratio is at 0.67.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 17 ’25 when Coen Steven P. sold 1,084 shares for $9.84 per share. The transaction valued at 10,669 led to the insider holds 10,679 shares of the business.
Dmytruk Mark E. bought 640 shares of DNA for $6,299 on Jul 17 ’25. On Jul 09 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 2,200 shares for $11.18 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 753890880 and an Enterprise Value of 671529600. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.18 while its Price-to-Book (P/B) ratio in mrq is 1.03. Its current Enterprise Value per Revenue stands at 2.828 whereas that against EBITDA is -2.065.
Stock Price History:
The Beta on a monthly basis for DNA is 1.52, which has changed by -0.12972975 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $16.85, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is 32.33%, while the 200-Day Moving Average is calculated to be 40.68%.
Shares Statistics:
The stock has traded on average 1.42M shares per day over the past 3-months and 2061270 shares per day over the last 10 days, according to various share statistics. A total of 43.08M shares are outstanding, with a floating share count of 38.16M. Insiders hold about 31.29% of the company’s shares, while institutions hold 57.35% stake in the company. Shares short for DNA as of 1752537600 were 10340727 with a Short Ratio of 7.29, compared to 1749772800 on 11312529. Therefore, it implies a Short% of Shares Outstanding of 10340727 and a Short% of Float of 22.91.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
4 analysts predict $41.6M in revenue for the current quarter. It ranges from a high estimate of $42.7M to a low estimate of $40.8M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $56.21MFor the next quarter, 4 analysts are estimating revenue of $43.93M. There is a high estimate of $44.37M for the next quarter, whereas the lowest estimate is $43.4M.
A total of 4 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $179.9M, while the lowest revenue estimate was $175.75M, resulting in an average revenue estimate of $178.2M. In the same quarter a year ago, actual revenue was $227.04MBased on 4 analysts’ estimates, the company’s revenue will be $206.56M in the next fiscal year. The high estimate is $220.01M and the low estimate is $193.5M.
